The small-cap health and bio space delivered a mix of financial confirmation and strategic progress. Tristel reaffirmed its full-year results landed in line with expectations, while Frontier IP's portfolio company Cambridge Raman Imaging (AIM:FIPP) secured fresh EU grant funding to push into pharmaceutical quality control, and ImmuPharma advanced its Kapiglucagon programme by naming a manufacturing partner.
Tristel confirms full-year growth targets met
Tristel (LON:TSTL) confirmed its full-year results came in line with expectations, with shares edging up to 386.5p, a gain of 0.39% on the day. Interim chief executive Anna Wasyl said the group continued to meet its performance targets of delivering double-digit revenue growth each year while maintaining adjusted EBITDA margins of at least 25%, underlining the consistency of the infection-control specialist's operating model. Chris Lee was also named alongside the results update.
Cambridge Raman Imaging lands EU grant for pharma push
Frontier IP Group (LON:FIPP) saw its portfolio company Cambridge Raman Imaging secure a non-dilutive €400,000 grant from the European Union, funding that will support a strategic shift toward industrial pharmaceutical quality control inspection. The company is targeting a market it expects to triple in size by 2033, giving Frontier IP a fresh growth angle within its stable of university spinouts. Frontier IP shares rose 1.43% to 13.44p, with Francesco Crisafi named in connection with the development.
ImmuPharma names Thermo Fisher for Kapiglucagon supply
ImmuPharma (LON:IMM) selected Thermo Fisher as drug product contract development and manufacturing organisation for its Kapiglucagon programme, a milestone in preparing the candidate for further clinical development. Dr Sébastien Goudreau said the company was pleased to bring Thermo Fisher on board for the DP CDMO role. The shares fell 6.667% to 4.2p, even as the manufacturing tie-up marks a concrete step toward advancing the programme.
